You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CAFFEINE CITRATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for CAFFEINE CITRATE
Drug Prices for CAFFEINE CITRATE

See drug prices for CAFFEINE CITRATE

Recent Clinical Trials for CAFFEINE CITRATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Al-Azhar UniversityEarly Phase 1
AmgenEarly Phase 1
University of MichiganPhase 2

See all CAFFEINE CITRATE clinical trials

Pharmacology for CAFFEINE CITRATE
Medical Subject Heading (MeSH) Categories for CAFFEINE CITRATE

US Patents and Regulatory Information for CAFFEINE CITRATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exela Pharma CAFFEINE CITRATE caffeine citrate SOLUTION;ORAL 077304-001 Sep 21, 2006 AA RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Exela Pharma Science CAFFEINE CITRATE caffeine citrate SOLUTION;INTRAVENOUS 077233-001 Sep 21, 2006 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Micro Labs CAFFEINE CITRATE caffeine citrate SOLUTION;ORAL 213202-001 Dec 16, 2019 AA RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma CAFCIT caffeine citrate SOLUTION;ORAL 020793-002 Apr 12, 2000 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sun Pharm CAFFEINE CITRATE caffeine citrate SOLUTION;ORAL 090357-001 Sep 30, 2009 AA RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Micro Labs CAFFEINE CITRATE caffeine citrate SOLUTION;INTRAVENOUS 207400-001 Dec 14, 2017 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for CAFFEINE CITRATE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Gennisium Pharma Gencebok caffeine citrate EMEA/H/C/005435
Treatment of primary apnoea of premature newborns.
Authorised no no no 2020-08-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.